Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Number of Human Papillomavirus Vaccine Doses and Condyloma

Number of Human Papillomavirus Vaccine Doses and Condyloma Letters for Planning and Evaluation at the US Department of Health and Human In the current analysis, prevalent infections may have dispro- Services. No other disclosures were reported. portionately affected girls receiving fewer than 3 doses: sen- Funding/Support: Dr Chua was supported by funding from the Harvard PhD sitivity analyses that accounted for cases occurring within Program in Health Policy. months immediately after vaccination by lengthening the “buf- Role of the Sponsor: The Harvard PhD Program in Health Policy had no role in fer period” between vaccination and case counting showed a the design and conduct of the study; collection, management, analysis, and decrease in risk of condyloma, especially among the young- interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. est girls most likely to have been recently exposed. Use of the Disclaimer: This was written entirely in Dr Sommers’ capacity as a Harvard 12-month buffer made the incident rate ratios (IRRs) for girls employee and does not represent the views of US Department of Health and who received 1, 2, and 3 doses nearly identical (IRRs, 0.24, 0.19, Human Services. and 0.19, respectively) compared with unvaccinated girls http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Number of Human Papillomavirus Vaccine Doses and Condyloma

Kreimer, Aimée R.; Safaeian, Mahboobeh; Hildesheim, Allan
JAMA , Volume 311 (23) – Jun 18, 2014
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/number-of-human-papillomavirus-vaccine-doses-and-condyloma-YtNcSDkh2N

References (10)

Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2014.5009
pmid
24938569
Publisher site
See Article on Publisher Site

Abstract

Letters for Planning and Evaluation at the US Department of Health and Human In the current analysis, prevalent infections may have dispro- Services. No other disclosures were reported. portionately affected girls receiving fewer than 3 doses: sen- Funding/Support: Dr Chua was supported by funding from the Harvard PhD sitivity analyses that accounted for cases occurring within Program in Health Policy. months immediately after vaccination by lengthening the “buf- Role of the Sponsor: The Harvard PhD Program in Health Policy had no role in fer period” between vaccination and case counting showed a the design and conduct of the study; collection, management, analysis, and decrease in risk of condyloma, especially among the young- interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. est girls most likely to have been recently exposed. Use of the Disclaimer: This was written entirely in Dr Sommers’ capacity as a Harvard 12-month buffer made the incident rate ratios (IRRs) for girls employee and does not represent the views of US Department of Health and who received 1, 2, and 3 doses nearly identical (IRRs, 0.24, 0.19, Human Services. and 0.19, respectively) compared with unvaccinated girls

Journal

JAMA – American Medical Association

Published: Jun 18, 2014

There are no references for this article.